That's Sir Andrew Witty to you

All that talk about re-investing in Britain has paid off. GlaxoSmithKline ($GSK) CEO Andrew Witty (photo) was honored with a knighthood over New Year's after he promised increased spending on domestic facilities, staff and development. GSK's discounted pricing in poor countries must have helped, too. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.